Lung Cancer

Precision medicine bugged by imprecise biopsy samples

The idealistic vision of precision oncology targeting tumours based on oncogene signatures has to overcome the current reality of unsatisfactory paraffin-fixed biopsy samples that can’t provide enough DNA for genome analysis, a conference has been told. Speaking at the Australasian Lung Cancer trials Group (ALTG) Annual Scientific Meeting in Sydney, Dr Katia Nones (PhD) a ...

Already a member?

Login to keep reading.

© 2022 the limbic